Blog

DEEP RESEARCH · LG CHEM 051910

LG Chem deep dive: three new growth engines and a geopolitical-risk playbook

From a traditional petrochemical company to a "global science company" — funding, IRA FEOC response, and JV restructuring in one place

Date: 2025-09-10 · Single-name deep dive · Naver Blog · synthesized from filings & news

All investment decisions are your own responsibility. This is research, not a buy or sell recommendation.

0. Bottom line first

LG Chem is rotating from traditional petrochemicals into battery materials, sustainable materials, and innovative drugs. 2023 consolidated revenue was about KRW 55.25 trillion (including LG Energy Solution). Two simultaneous challenges: (1) a long petrochemical downturn driven by Chinese oversupply, (2) the US IRA — especially the FEOC rule — forcing a rework of Chinese JVs. A series of exchangeable bond (EB) issuances totaling roughly KRW 4 trillion (~USD 3 billion) has given the company the strategic firepower to fund growth and meet regulations at the same time.

LG Chem's four-axis transformationShrink old petchem, fund new growth, pass global regulation
Battery materialsTennessee · LFP · NCM/NCMA
Sustainable materialsRecycled & bio-plastics
Innovative drugsAVEO acquisition · gout · obesity
Restructuring25% NCC cut · GS Caltex JV proposal
Lighten petchem, weight up growth, rebuild the global supply chain as "non-FEOC"

1. Core business and trends

1.1 Business model and major revenue sources

Official fact: LG Chem operates in five segments — Petrochemicals, Advanced Materials, Life Sciences, LG Energy Solution (subsidiary, spun off Dec 2020), and Common & Others (e.g. Farmhannong). The largest revenue contributors are LG Energy Solution and traditional petrochemicals.

The table below shows quarterly revenue by segment (consolidated, KRW trillion).

KRW trillion2023 Q42024 Q12024 Q32025 Q2
Petrochemicals4.264.464.814.97
Advanced Materials1.321.581.711.73
Life Sciences0.300.280.310.40
LG Energy Solution8.006.136.886.16
Common & Others0.150.250.110.24
Total13.1311.6112.6712.30

Interpretation: Advanced Materials wobbled in 2023 Q4 on weak European demand and customer destocking, then recovered from 2024 Q1. Petrochemicals turned profitable again in 2025 Q2 despite a tough market, and Life Sciences benefited from licensing-out fees for a rare-obesity drug. LG Energy Solution kept a steady share of group revenue via North American customer volume growth.

1.2 Industry outlook by segment

Petrochemicals

Supply/demand recovery 2028–2030

Structural oversupply from massive Chinese capacity adds. Analysts expect rebalancing only around 2028–2030, via shutdowns and slower additions. LG Chem is shifting to high-value specialty products and divesting non-core NCCs.

Advanced Materials (battery)

Cathode market 15% CAGR through 2035

The hot trend is cost-competitive LFP, currently dominated by Chinese players. A threat and an opportunity for NCM-heavy LG Chem — it has officially entered LFP and is building a North America-centric supply chain for the IRA.

Life Sciences

Pharma 6.5% CAGR through 2035

GLP-1 obesity/diabetes drugs and immuno-oncology drive growth. LG Chem acquired US oncology company AVEO in 2023 to strengthen its pipeline.

2. Competitive environment and economic moat

2.1 Key competitors

  • Petrochemicals: Domestic — Lotte Chemical, Hanwha Solutions. Global — BASF (Germany), Sinopec (China), Dow (US).
  • Advanced Materials (cathode): Domestic — EcoPro, POSCO Future M. Global — Umicore (Belgium) and many Chinese players.
  • Life Sciences: Growth hormone Eutropin holds the #1 Korean share (~46%); diabetes drug Zemiglo is top tier in the DPP-4 market.

2.2 Economic moat

  1. Diversified portfolio: Petchem weakness partly offset by Advanced Materials and Life Sciences growth.
  2. Scale and market share: Strong Korean share in PVC, ABS, and select petchem products.
  3. R&D capacity: Group R&D (excl. LGES) crossed KRW 1 trillion for the first time in 2023, focused on new drugs and next-gen battery materials.
  4. Global customer base: Deep partnerships with GM, Toyota, Volkswagen and other major OEMs.

2.3 Defending the moat

Total KRW 10 trillion investment plan through 2025 — most of it on battery materials. IRA-driven supply chain re-engineering plus strategic M&A (AVEO) keeps the company responsive to external shocks.

2.4 COGS ratio

COGS ratio: ~80.7% (2022) → ~84.1% (2023) → ~84.6% (2024), an uptrend. Highly sensitive to naphtha, lithium, and nickel prices. LG Chem is countering via raw-material insourcing, long-term contracts, process innovation, and battery recycling — all part of vertical integration.

2.5 Petchem competition and restructuring — LG Chem vs Lotte Chemical

In August 2025, the Korean government's "Petrochemical Industry Reboot Plan" demanded NCC capacity cuts of up to 25%. LG Chem and Lotte Chemical must submit concrete restructuring plans by year-end.

2025 Q2LG ChemLotte Chemical
Total revenueKRW 12.30TKRW 4.20T
Petrochemicals (base)KRW 4.97T (40.4%)KRW 2.69T (64.0%)
Advanced MaterialsKRW 1.73T (14.1%)KRW 1.05T (24.9%)
Life SciencesKRW 0.40T (3.3%)—
Battery materials / Energy SolutionKRW 6.16T (50.1%)—

Official fact: LG Chem proposed a JV with GS Caltex to integrate Yeosu NCC operations — a vertical-integration model linking naphtha sourcing with production. It is also running voluntary retirement under the wage-peak system and divesting non-core assets.

Interpretation: In the same downturn, LG Chem's petchem share is around 40%, vs Lotte Chemical's 64%. LG Chem moved into diversification earlier, so it has more shock absorbers. That's the structural difference.

3. Short- and mid-term outlook

3.1 2025–2026 key items

Petchem is a slow recovery; EV demand softening is a drag on Advanced Materials. Changes to the IRA following the US election are the single biggest uncertainty. Near-term swing factors: construction progress at Tennessee and Morocco plus visible petchem restructuring results.

3.2 The three growth engines for the next three years

Three new growth enginesLong-term thrust
Battery materialsTennessee cathode + LFP diversification
Sustainable materialsRecycled & bio-plastics
Innovative drugsAVEO oncology + gout/obesity
Cash-flow discipline2025 CapEx cut by ~KRW 1T
Keep investing — but pace it to the market

4. IRA response and global supply-chain redesign

4.1 IRA FEOC rule and the Gumi precedent

Official fact: A company is designated FEOC if a Chinese, Russian, Iranian, or North Korean government directly or indirectly owns, controls, or directs 25% or more of board seats, voting rights, or equity. EVs using FEOC components or minerals lose the US tax credit. The rule applies in stages: battery components from 2024, critical minerals from 2025.

Official fact — Gumi (LG-HY BCM): Originally LG Chem 51% / Huayou Cobalt 49% → Japan's Toyota Tsusho acquired 25% from Huayou, restructuring the ownership to LG Chem 51% / Toyota Tsusho 25% / Huayou Cobalt 24%. Huayou's stake dropped below the 25% threshold, satisfying FEOC.

4.2 Chinese JV portfolio — FEOC risk

JV / locationChinese partnerPurposeOwnershipFEOC complianceStrategic note
LG-HY BCM (Gumi)Huayou CobaltNCM/NCMA cathodeLG Chem 51% / Toyota Tsusho 25% / Huayou 24%Compliant (restructured)Blueprint for compliance — was originally Huayou 49%
Wuxi cathode JV (China)Huayou CobaltNCM cathodeLG Chem 51% / Huayou 49%Non-compliantSame original structure as Gumi — restructuring needed for North America inclusion
Quzhou precursor JV (China)Huayou CobaltNCM precursorLG Chem 49% / Huayou 51%Non-compliantChinese-majority — severe risk; directly hits IRA "critical mineral" rule
Morocco LFP cathode projectHuayou GroupLFP cathodeTBD (MOU)To be decidedMOU explicitly says "adjust equity ratio to comply with FEOC"
Saemangeum precursor (Korea)Huayou CobaltNCM precursorTBD (planned)To be decidedKorea = US FTA partner — designed as compliant from the start

4.3 Estimated restructuring cost

Official fact: Extrapolating from the Gumi precedent, restructuring Wuxi and Quzhou to FEOC-compliant ownership could require roughly USD 2.5–2.7 billion — strikingly close to the size of LG Chem's recent funding round.

5. Financial and investment analysis

5.1 Cash flow — "invest for growth, raise to invest"

  • Operating CF: Volatile but consistently positive — basic cash generation intact.
  • Investing CF: Persistently large negative due to CapEx on the three growth engines.
  • Financing CF: Positive — funded by borrowings and exchangeable bonds.

5.2 Potential overhang — exchangeable bond (EB) analysis

Official fact: Using its LG Energy Solution stake (81.84%) as the underlying, LG Chem issued several large foreign-currency EBs. Recently: USD 2.0B (~KRW 2.6T) + KRW 1.4T, totaling roughly KRW 4T (~USD 3B).

  • Stated use of proceeds: CapEx and operating funds for sustainable materials, battery materials, and new drugs, plus refinancing existing debt.
  • Strategic meaning: Beyond the stated purpose, this is also strategic firepower for FEOC-driven JV restructuring. Leaving the use of proceeds open gives LG Chem leverage in negotiations with Chinese partners — "strategic flexibility" to fund both growth and compliance.

Interpretation: The EBs may eventually convert into LGES stock, creating overhang. However, the exchange price was set at a meaningful premium to the share price at issuance, which limits near-term pressure.

6. Shareholders and capital return

Official fact: Early 2025 — largest shareholder (LG) Corp. and related parties ~35%, National Pension Service ~8.6%.

Metric202120222023
DPS (common, KRW)12,00010,0003,500
Payout ratio (consolidated)25.5%20.5%—

For 2023–2025, the dividend policy is held at ~20% of consolidated net income to concentrate cash on the three growth engines. Once investment bears fruit and cash flow normalizes, LG Chem plans to consider raising the payout ratio to over 30%.

What the 2025 EB raise is really forThe four uses of ~USD 3B
Growth CapExBattery, sustainable materials, drugs
Debt refinancingRoll existing maturities
FEOC responseWuxi/Quzhou restructuring USD 2.5–2.7B
Strategic flexLeverage in JV negotiations
Raise size (~USD 3B) ≈ estimated restructuring cost — by design, not coincidence

7. Overall conclusion

Official fact: LG Chem is running legacy restructuring and new-growth investment in parallel, and has reduced 2025 CapEx by roughly KRW 1+ trillion to prioritize cash-flow management.

Interpretation: Three things will define LG Chem's future — (1) the success of petchem restructuring, (2) building a North America-centric battery-materials supply chain, and (3) visible progress in the drug pipeline. The ~KRW 4T EB raise isn't just a funding event — it's a deliberate move to fund growth and regulatory compliance in a single stroke.

Sources

Naver original